Dixie Lee Esseltine
Gupta N, Goh Y, Min C, Lee J, Kim K, Wong R, et al
. Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. J Hematol Oncol. 2015;8:103 pubmed publisher
..0 mg. Consequently, East Asian patients enrolled in phase 3 studies are receiving the same ixazomib dose as patients in other regions. This study is registered at NCT01645930. ..